Ousia Pharma, a Copenhagen, Denmark-based biotech company providing a new drug class for obesity, raised an undisclosed amount in Seed funding.
Omega Funds made the investment.
The company intends to use the funds to support the preclinical and clinical development of its once-weekly, dual-incretin-NMDA receptor antagonist conjugate.
Led by CEO Anders B. Klein, Ousia Pharma is a private biotech company spun out from the University of Copenhagen that is developing new peptide-drug conjugates to treat obesity and metabolic diseases. It has provided a drug-targeting approach that leverages incretin hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain’s appetite control centers.
In conjunction with this financing, Prof. Sir Mene Pangalos, former Executive Vice President of BioPharmaceuticals R&D at AstraZeneca and current Omega Funds Venture Partner, as well as Dr. Elisabeth Bjӧrk, former Senior Vice President of Cardiovascular, Renal, and Metabolism R&D at AstraZeneca, and Dr. Otello Stampacchia, Founder and Managing Director of Omega Funds, will join Ousia’s Board of Directors
FinSMEs
06/05/2025